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Globally, over 10% of pregnancies result in preterm delivery1. Preterm birth is 
the leading cause of mortality among children under 5 years old,  and children 
who survive preterm delivery are at increased risk of long term morbidity 
including neurodevelopmental delay and chronic lung disease2,3. Several 
interventions have been shown to increase prognosis in preterm labour, such as 
appropriate administration of antenatal corticosteroids4. According to NICE 
guidelines, in women who are found to have exposed membranes between 16 
and 27+6 weeks gestation insertion of an emergency cervical cerclage can be 
considered to reduce the risk of preterm delivery and to prolong gestation to 
delivery5.  Insertion of an emergency cervical cerclage has been found to delay 
delivery by approximately 5 weeks6,7. However, emergency cervical cerclage is 
associated with maternal risks including an increased chance of miscarriage, 
chorioamnionitis and subsequent need for delivery by Caesarean Section8. It has 
previously been shown that the overall gestational age at delivery, suture 
insertion to delivery interval, and neonatal outcome for those cases with visible 
membranes at the time of cerclage insertion were considerably worse than for 
those women with no visible membranes (median gestational age at delivery, 
24+2 vs 37+5 weeks gestation; median suture insertion to delivery interval, 19 vs 
117 days; fetal survival rates, 50% vs 91%)9. 
 
Fetal fibronectin (fFN) is an extracellular matrix glycoprotein located between 
the decidua and the trophoblast. Disruption of this interface results in release of 
fFN into the cervicovaginal fluid. Our group has previously demonstrated the 
predictive value of quantitative fFN measurement in women presenting with 
symptoms of preterm labour, with added risk discrimination over and above the 
traditional qualitative test, as well as in asymptomatic women at high risk of 
preterm birth10. Furthermore, we have shown that even in women with exposed 
membranes, a group traditionally thought to be at universally high risk of 
preterm birth, the risk of preterm birth still correlates with qfFN concentration 
in the cervicovaginal fluid11.  
 
The purpose of this study is to determine the predictive value of quantitative fFN 
for preterm delivery among women with exposed membranes undergoing 
emergency cervical cerclage insertion.  
 
Material and Methods  
 
This is a retrospective observational study performed between 2015 and 2018 at 
St Thomas’ Hospital, London, a tertiary level Obstetrics unit.  
 
The study had ethical approval under the Preterm Birth Clinical Network 
Database (Research Ethics Committee (REC) Reference 16/ES/0093)12. Women 
were recruited to the study if they had singleton pregnancies, and were 
considered high-risk for preterm birth (one or more of: previous sPTB <37 
weeks’ gestation; previous second-trimester miscarriage ≥16 weeks; previous 
invasive cervical surgery; uterine abnormality; incidental finding of a short 
cervix <15mm). Women were included in the analysis at the time they had 
exposed membranes noted at speculum or during cervical cerclage insertion 
(with any degree of cervical dilatation), if they were between 18 and 24 weeks of 
gestation, were not contracting, and underwent quantitative fFN concentration 
measurements within 24 hours prior to emergency cerclage insertion (Hologic 
Rapid fFN 10Q). fFN testing was performed prior to ultrasound scan or digital 
examination using previously described methods, in line with the manufacturer's 
guidelines. Briefly, during speculum examination, a swab was inserted into the 
posterior fornix and rotated for 10 seconds until saturated, avoiding the cervix 
and fetal membranes. A single aliquot (200 μl) of the sample was analysed with 
the conventional qualitative analyser. Women with blood stained CVF samples, 
sexual intercourse in the previous 24 h, or suspected/confirmed rupture of 
membranes were excluded from the analysis, due to known interference with 
fFN measurement.  
 
The primary outcome for analysis was spontaneous PTB within 28 days from 
testing (as the median gestational age of cerclage insertion is 20 weeks gestation 
with an aim to prolong gestation to fetal viability at 23-24 weeks gestation) with 
additional outcomes of spontaneous PTB within 14 days and prior to 28, 34 and 
37 weeks of gestation as well as latency from cerclage insertion to delivery. All 
statistical analyses were performed with GraphPad Prism software version 8.0. 
P<0.05 was considered statistically significant. Previously established thresholds 
of qfFN (10, 50, 200, 500 ng/ml) were used to determine sensitivity, specificity, 
positive and negative predictive values, and relative risk13. This study is reported 





35 women met the inclusion criteria. The demographic and clinical 
characteristics of the 35 women eligible for analysis are described in Table 1. 
17% had a history of spontaneous preterm birth and 46% had a history of 
second trimester miscarriage. One woman (3%) had a previous history of 
cervical surgery.  Median gestational age at insertion of cervical cerclage was 
20+2 weeks (LQ-UQ; 18+6 - 21+2 weeks). Median gestational age at delivery was 
29+2 weeks (23+2 - 38+3 weeks) (Table 1). 
 
Table 2 describes the distribution of women in each qfFN category and the rates 
of sPTB in each group. In total, 12 women (34%) delivered within 28 days of 
cervical cerclage insertion and 21 women (62%) delivered before 37 weeks 
gestation (Table 2).  60% of women with an fFN level above 500ng/mL delivered 
within 28 days of cerclage insertion, and they all delivered before 37 weeks 
gestation. No women with fFN levels below 10ng/mL delivered within 14 or 28 
days and 75% of them delivered at term.  
 
The median time from cervical cerclage insertion to delivery was 65.5 days (17 - 
126.5 days) (Table 1). Spearman's rank-order correlation was significant 
between fFN concentration at time of cerclage and number of days to delivery 
(rs=−0.52, p=0.0016), which appeared to follow a linear trend (Figure 1). Mann–
Whitney U analysis demonstrated a significant difference in the distribution of 
qfFN concentrations in women who delivered preterm compared to those who 
did not, both within 28 days from the cerclage (p=0.0048) and those less than 37 
weeks gestation (p=0.006).  
 
Predictive statistics for sPTB within 28 days of cerclage insertion and prior to 37 
weeks of gestation using qfFN are described in Table 3 and 4, respectively. For 
delivery within 28 days, fFN ≥ 200 ng/mL had a 72% sensitivity and 63% 
specificity (Table 3). For delivery before 37 weeks, fFN ≥ 10 ng/mL had 95% 
sensitivity, while fFN ≥ 500 ng/mL had 100% specificity (Table 4). There is a 
significant difference in time to delivery based on a qfFN threshold of >200 
ng/mL; woman with a fFN value of 0-199 ng/ml had a median time to delivery of 
124 days (range 68-140 days), whereas women with a fFN >200ng/ml had a 
median time to delivery of 29 days (range 12-75) (p = 0.0014). This is 
represented in a Kaplan Meier survival curve comparing the gestations at 
delivery between women with fFN levels<200ng/mL and those with fFN 




This study demonstrates the prognostic value of pre-cerclage qfFN levels to 
predict spontaneous PTB in women with exposed membranes. Our results show 
that the risk of preterm birth correlates with qfFN concentration in CVF even in 
women with exposed membranes, a group generally considered to be at 
extremely high risk of preterm birth. It is likely the leakage of fFN represents an 
active inflammatory process, related to risk of delivery following chorio-decidual 
disruption, rather than a mechanism solely related to close proximity of the 
exposed membranes to the vagina. 
  
There is a significant negative correlation between pre-cervical cerclage fFN and 
risk of preterm delivery. Women with a pre-cerclage fFN of 0-199ng/ml are 
significantly less likely to have preterm delivery than women with an fFN 
>200ng/ml. Women with an fFN of >500ng/ml were shown to be at extremely 
high risk of preterm delivery.  
 
Women with exposed but with low concentrations (<200ng/mL) of 
cervicovaginal fFN levels have a low risk of subsequent delivery before 37 weeks 
after cerclage insertion compared with women with higher concentrations 
(>200ng/mL) of qfFN (RR = 2.8, 1.5-6.3). In this cohort, no women with qfFN <10 
ng/mL delivered within 28 days, whilst 40% of those with qfFN concentrations 
≥200 ng/mL and 60% women with qfFN ≥500 ng/mL delivered within this time 
frame. Furthermore, the positive prediction of qfFN at thresholds of 200 ng/ml 
was superior to the traditionally used qualitative test (threshold of 50 ng/ml), 
whilst maintaining good negative prediction. However, exposed fetal membranes 
and the use of emergency cerclage remain rare events and as such highly 
powered statistical analysis has not been possible in this study. 
 
To our knowledge, this is the first study looking at the prognostic value of fFN 
among women requiring emergency cerclage for exposed membranes. Our group 
has previously demonstrated the prognostic value of fFN among women with 
risk factors for preterm labour but without exposed membranes10 and more 
recently with exposed membranes11.  
 
Currently the routine use of fetal fibronectin tests in women with exposed fetal 
membranes is not often performed, nor is it recommended14. However, this 
study suggests a role for the test in determining risk of preterm delivery and also 
the likelihood of reaching viability amongst women with exposed fetal 
membranes who are suitable for emergency cerclage. Given the high failure rate 
of this type of cerclage and the associated maternal septic morbidity that can be 
serious and potentially require ITU admission and result in end-organ damage, 
having this test to aid in clinical decision making seems prudent. It may support 
the clinician’s decision not to intervene in certain situations and accept a poor 
outcome, in order to do no harm. Furthermore, quantitative fFN in this group 
could have wider implications on other interventions for the management of 
threatened preterm delivery such as antenatal steroids and magnesium sulphate 
use, as well as transfer to tertiary neonatal units after 24 weeks’ gestation.  
 
Nonetheless, larger studies of quantitative fFN in this group of patients are 
required to confirm its accuracy and also to confirm test thresholds with the 
highest positive predictive values. Given the rarity of cervical cerclage for 
exposed fetal membranes, this would likely need to be done across multiple sites 
to improve homogeneity and to provide sufficient statistical power. Future work 
could also determine whether the insertion of an emergency cervical cerclage 




The use of cervicovaginal quantitative fFN levels in women presenting with 
exposed membranes between 18+0-23+6 weeks gestation with no 
contraindications to cervical cerclage is beneficial in providing information on 
the risk of preterm delivery. Given the serious maternal and fetal risks associated 
with emergency cerclage surgery, qfFN could be used to counsel these patients at 
high risk of preterm delivery as well as potentially assisting in the clinical 
decision to insert a cerclage. 
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